- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
This study is testing a new vaccine (mRNA-1647) to see if it can prevent cytomegalovirus (CMV) infection in healthy people. We want to know how well it works, if it's safe, and how a person's body reacts to it. The vaccine is given to adults aged 16 to 40.
For: Cytomegalovirus Infection (CMV)Finland · Italy · Spain - Active not recruitingPHASE1, PHASE2
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
This study is looking into an experimental vaccine for Cytomegalovirus (CMV), a common virus. It aims to check its safety and how well it helps the body fight off the virus in healthy young people aged 9 to 25.
For: CytomegalovirusUnited States · Canada · United Kingdom